Blockchain Registration Transaction Record

GeoVax to Present Single-Dose MVA and Continuous Cell-Line Manufacturing Advances at World Vaccine Congress Europe 2026

GeoVax to present at World Vaccine Congress Europe 2026 on single-dose MVA-X and continuous cell-line manufacturing, advancing scalable vaccine production.

This news matters because it signals a potential paradigm shift in vaccine development and deployment. Traditional MVA vaccines often require multiple doses and rely on cumbersome primary-cell manufacturing, which can limit rapid scale-up during outbreaks. GeoVax’s single-dose MVA-X, if successful, could simplify immunization campaigns, improve compliance, and enable faster response to public health emergencies such as mpox or smallpox. The continuous cell-line manufacturing platform offers a more scalable and reproducible production method, reducing dependence on chicken embryo fibroblasts and facilitating technology transfer to local manufacturers. Together, these innovations could enhance global vaccine supply, support biodefense stockpiling, and expand access to life-saving vaccines in resource-limited settings. As GeoVax advances its lead program GEO-MVA toward a Phase 3 trial, these technological breakthroughs may also attract partnerships and funding, accelerating the fight against high-consequence infectious diseases.